• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Aethlon Medical to Present at 5th International Bird Flu Summit

Posted on: Thursday, 20 September 2007, 09:00 CDT

Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce will give a presentation at the 5th International Bird Flu Summit on September 27th. Mr. Joyce's presentation is entitled, The Aethlon Hemopurifier® as a Treatment for Drug Resistant Avian Flu. The event will take place at the Thomas & Mack Center in Las Vegas, Nevada. Additional information, including the speaker agenda, can be accessed online at: http://new-fields.com/birdflu5/viewAgenda.php?newsid=2

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®, a first-in-class medical device to treat infectious disease. The Hemopurifier® addresses the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. Regulatory and commercialization initiatives in the United States are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Collaborative studies to demonstrate utility of the Hemopurifier® are being conducted with researchers at the Government of India's National Institute of Virology (NIV), The Centers for Disease Control and Prevention (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and The Southwest Foundation for Biomedical Research (SFBR). Aethlon recently demonstrated safety of the Hemopurifier® in a 24-treatment human study and has received approval to continue further human studies at The Fortis Hospital in India. The Company has also submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier® as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information on Aethlon Medical and its Hemopurifier® technology can be accessed at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc., to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Source: Business Wire

More News in this Category